23 Apr 2008 - Gene Bridges GmbH announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed.
Dr. Alan Berry, Director, Microbial Physiology and HTS at Novozymes Inc. in Davis, CA said: "The Red/ET system is a very powerful technology, and we look forward to using it to accelerate our strain development efforts."
Red/ET is a method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome, according to the company.
 |
www.bionity.com/news/e/81110 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/81110 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |